Marc A Riedl

List of Publications by Year in Descending Order

92 papers	3,410 citations	28 h-index	57 g-index
98 ext. papers	4,183 ext. citations	7.1 avg, IF	5.31 L-index

#	Paper	IF	Citations
92	The international WAO/EAACI guideline for the management of hereditary angioedema - the 2021 revision and update.. *Allergy: European Journal of Allergy and Clinical Immunology*, **2022**,	9.3	6
91	The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.. *World Allergy Organization Journal*, **2022**, 15, 100627	5.2	6
90	Inhibition of Prekallikrein for Hereditary Angioedema.. *New England Journal of Medicine*, **2022**, 386, 1026-1033	59.6	1
89	Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial. *Journal of Allergy and Clinical Immunology*, **2021**, 148, 164-172.e9	11.5	29
88	Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report. *Allergy, Asthma and Clinical Immunology*, **2021**, 17, 40	3.2	5
87	Consensus on treatment goals in hereditary angioedema: A global Delphi initiative. *Journal of Allergy and Clinical Immunology*, **2021**, 148, 1526-1532	11.5	3
86	Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema. *Clinical Reviews in Allergy and Immunology*, **2021**, 61, 84-97	12.3	3
85	CaregiversTrole in managing hereditary angioedema and perceptions of treatment-related burden. *Allergy and Asthma Proceedings*, **2021**, 42, S11-S16	2.6	5
84	Insights into the treatment burden of hereditary angioedema in the evolving treatment landscape. *Allergy and Asthma Proceedings*, **2021**, 42, S1-S3	2.6	3
83	Physician and patient perspectives on the management of hereditary angioedema: a survey on treatment burden and needs. *Allergy and Asthma Proceedings*, **2021**, 42, S17-S25	2.6	5
82	Patient perspectives on the treatment burden of injectable medication for hereditary angioedema. *Allergy and Asthma Proceedings*, **2021**, 42, S4-S10	2.6	9
81	Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study. *Clinical and Experimental Allergy*, **2021**, 51, 1391-1395	4.1	1
80	Current medical management of hereditary angioedema: Follow-up survey of US physicians. *Annals of Allergy, Asthma and Immunology*, **2021**, 126, 264-272	3.2	6
79	US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. *Journal of Allergy and Clinical Immunology: in Practice*, **2021**, 9, 132-150.e3	5.4	52
78	Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. *Allergy: European Journal of Allergy and Clinical Immunology*, **2021**, 76, 1188-1198	9.3	11
77	Androgen use in hereditary angioedema: A critical appraisal and approaches to transitioning from androgens to other therapies. *Allergy and Asthma Proceedings*, **2021**, 42, 22-29	2.6	6
76	Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study. *Orphanet Journal of Rare Diseases*, **2021**, 16, 86	4.2	4

75	Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study. *Allergy: European Journal of Allergy and Clinical Immunology*, **2021**,	9.3	3
74	COVID-19 and hereditary angioedema: Incidence, outcomes, and mechanistic implications. *Allergy and Asthma Proceedings*, **2021**, 42, 506-514	2.6	4
73	Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. *Allergy: European Journal of Allergy and Clinical Immunology*, **2020**, 75, 2879-2887	9.3	17
72	Association Between Self-Reported Dental Hygiene Practices and Dental Procedure-Related Recurrent Angioedema Attacks in HAE Subjects: A Multicenter Survey. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 3162-3169.e5	5.4	1
71	Long-term safety and efficacy of subcutaneous C1-inhibitor in older patients with hereditary angioedema. *Annals of Allergy, Asthma and Immunology*, **2020**, 125, 334-340.e1	3.2	2
70	Experience with Intravenous Plasma-Derived C1-Inhibitor in Pregnant Women with Hereditary Angioedema: A Systematic Literature Review. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 1875-1880.e3	5.4	4
69	Definition, aims, and implementation of GA LEN/HAEi Angioedema Centers of Reference and Excellence. *Allergy: European Journal of Allergy and Clinical Immunology*, **2020**, 75, 2115-2123	9.3	10
68	Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial. *Allergy, Asthma and Clinical Immunology*, **2020**, 16, 8	3.2	6
67	International Consensus on the Use of Genetics in the Management of Hereditary Angioedema. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 901-911	5.4	28
66	Hereditary angioedema and shared decision making. *Allergy and Asthma Proceedings*, **2020**, 41, S55-S60	2.6	7
65	Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study. *Allergy, Asthma and Clinical Immunology*, **2019**, 15, 49	3.2	7
64	Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. *Journal of Allergy and Clinical Immunology: in Practice*, **2019**, 7, 1793-1802.e2	5.4	42
63	Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings. *Journal of Allergy and Clinical Immunology: in Practice*, **2019**, 7, 2035-2038	5.4	6
62	Update on the Use of C1-Esterase Inhibitor Replacement Therapy in the Acute and Prophylactic Treatment of Hereditary Angioedema. *Clinical Reviews in Allergy and Immunology*, **2019**, 56, 207-218	12.3	19
61	The International/Canadian Hereditary Angioedema Guideline. *Allergy, Asthma and Clinical Immunology*, **2019**, 15, 72	3.2	68
60	Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies. *BioDrugs*, **2019**, 33, 33-43	7.9	12
59	Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema. *Journal of Allergy and Clinical Immunology: in Practice*, **2018**, 6, 1733-1741.e3	5.4	48
58	C1 esterase inhibitor concentrates and attenuated androgens - AuthorsTreply. *Lancet, The*, **2018**, 391, 1356	40	1

57	The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. *World Allergy Organization Journal*, **2018**, 11, 5	5.2	34
56	Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study. *Allergy: European Journal of Allergy and Clinical Immunology*, **2018**, 73, 1871-1880	9.3	24
55	Long-term prophylaxis therapy in patients with hereditary angioedema with C1 inhibitor deficiency. *Annals of Allergy, Asthma and Immunology*, **2018**, 121, 673-679	3.2	18
54	Population pharmacokinetics of subcutaneous C1-inhibitor for prevention of attacks in patients with hereditary angioedema. *Clinical and Experimental Allergy*, **2018**, 48, 1325-1332	4.1	7
53	Hereditary angioedema from the patient's perspective: A follow-up patient survey. *Allergy and Asthma Proceedings*, **2018**, 39, 212-223	2.6	28
52	Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2018**, 320, 2108-2121	27.4	103
51	Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States. *Orphanet Journal of Rare Diseases*, **2018**, 13, 180	4.2	8
50	Efficacy of recombinant human C1 esterase inhibitor across anatomic locations in acute hereditary angioedema attacks. *Allergy and Asthma Proceedings*, **2018**, 39, 359-364	2.6	3
49	Threshold-stimulated kallikrein activity distinguishes bradykinin- from histamine-mediated angioedema. *Clinical and Experimental Allergy*, **2018**, 48, 1429-1438	4.1	25
48	Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis. *New England Journal of Medicine*, **2017**, 376, 717-728	59.2	99
47	Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents. *Journal of Allergy and Clinical Immunology: in Practice*, **2017**, 5, 1091-1097	5.4	8
46	Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks. *Annals of Allergy, Asthma and Immunology*, **2017**, 118, 452-455	3.2	9
45	Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor. *New England Journal of Medicine*, **2017**, 376, 1131-1140	59.2	118
44	Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation. *American Journal of Gastroenterology*, **2017**, 112, 1621	0.7	10
43	An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension. *Clinical and Translational Allergy*, **2017**, 7, 36	5.2	23
42	Utility of minor determinants for skin testing in inpatient penicillin allergy evaluation. *Annals of Allergy, Asthma and Immunology*, **2017**, 119, 258-261	3.2	10
41	Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. *Lancet, The*, **2017**, 390, 1595-1602	40	45
40	Patient satisfaction and experience with intravenously administered C1-inhibitor concentrates in the United States. *Annals of Allergy, Asthma and Immunology*, **2017**, 119, 59-64	3.2	23

39	Emerging Therapies in Hereditary Angioedema. *Immunology and Allergy Clinics of North America*, **2017**, 37, 585-595	3.3	16
38	Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility. *Journal of Allergy and Clinical Immunology: in Practice*, **2017**, 5, 442-447.e1	5.4	7
37	Emergency Department Management of Hereditary Angioedema Attacks: Patient Perspectives. *Journal of Allergy and Clinical Immunology: in Practice*, **2017**, 5, 128-134.e4	5.4	14
36	Recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks with upper airway involvement. *Allergy and Asthma Proceedings*, **2017**, 38, 462-466	2.6	7
35	Safety and Usage of C1-Inhibitor in Hereditary Angioedema: Berinert Registry Data. *Journal of Allergy and Clinical Immunology: in Practice*, **2016**, 4, 963-71	5.4	40
34	Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency. *Pediatrics*, **2016**, 138,	7.4	35
33	Managing the female patient with hereditary angioedema. *Womens Health*, **2016**, 12, 351-61	3	17
32	Cases of acquired C1 inhibitor deficiency treated with rituximab. *Journal of Allergy and Clinical Immunology: in Practice*, **2016**, 4, 987-8	5.4	3
31	Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks. *Journal of Allergy and Clinical Immunology: in Practice*, **2015**, 3, 417-23	5.4	29
30	Critical appraisal of androgen use in hereditary angioedema: a systematic review. *Annals of Allergy, Asthma and Immunology*, **2015**, 114, 281-288.e7	3.2	51
29	Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks. *Journal of Allergy and Clinical Immunology: in Practice*, **2015**, 3, 206-212.e4	5.4	23
28	Recombinant human C1 esterase inhibitor in the management of hereditary angioedema. *Clinical Drug Investigation*, **2015**, 35, 407-17	3.2	15
27	Factors associated with negative histamine control for penicillin allergy skin testing in the inpatient setting. *Annals of Allergy, Asthma and Immunology*, **2015**, 115, 33-8	3.2	15
26	Current state of hereditary angioedema management: a patient survey. *Allergy and Asthma Proceedings*, **2015**, 36, 213-7	2.6	58
25	Current medical management of hereditary angioedema: follow-up survey of US physicians. *Journal of Allergy and Clinical Immunology: in Practice*, **2015**, 3, 220-7	5.4	16
24	Comparison of chromogenic and ELISA functional C1 inhibitor tests in diagnosing hereditary angioedema. *Journal of Allergy and Clinical Immunology: in Practice*, **2015**, 3, 200-5	5.4	25
23	Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. *Allergy: European Journal of Allergy and Clinical Immunology*, **2014**, 69, 602-16	9.3	410
22	Reply: To PMID 24565612. *Journal of Allergy and Clinical Immunology: in Practice*, **2014**, 2, 239-40	5.4	

21	Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. *Annals of Allergy, Asthma and Immunology*, **2014**, 112, 163-169.e1	3.2	59
20	Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. *Annals of Allergy, Asthma and Immunology*, **2013**, 110, 295-9	3.2	47
19	Creating a comprehensive treatment plan for hereditary angioedema. *Immunology and Allergy Clinics of North America*, **2013**, 33, 471-85	3.3	17
18	US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. *Journal of Allergy and Clinical Immunology: in Practice*, **2013**, 1, 458-67	5.4	118
17	Hereditary angioedema with normal C1-INH (HAE type III). *Journal of Allergy and Clinical Immunology: in Practice*, **2013**, 1, 427-32	5.4	26
16	HAE update: special considerations in the female patient with hereditary angioedema. *Allergy and Asthma Proceedings*, **2013**, 34, 13-8	2.6	11
15	Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema. *American Journal of Rhinology and Allergy*, **2013**, 27, 517-21	2.4	3
14	Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial. *Annals of Allergy, Asthma and Immunology*, **2012**, 108, 49-53	3.2	26
13	Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. *Allergy and Asthma Proceedings*, **2012**, 33 Suppl 1, S145-56	2.6	121
12	Randomized placebo-controlled trial of the bradykinin B receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. *Annals of Allergy, Asthma and Immunology*, **2011**, 107, 529-37	3.2	158
11	Current medical management of hereditary angioedema: results from a large survey of US physicians. *Annals of Allergy, Asthma and Immunology*, **2011**, 106, 316-322.e4	3.2	31
10	New therapeutics in C1INH deficiency: a review of recent studies and advances. *Current Allergy and Asthma Reports*, **2011**, 11, 300-8	5.6	9
9	Update on the acute treatment of hereditary angioedema. *Allergy and Asthma Proceedings*, **2011**, 32, 11-6	2.6	4
8	Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. *New England Journal of Medicine*, **2010**, 363, 532-41	59.2	387
7	Response time for ecallantide treatment of acute hereditary angioedema attacks. *Annals of Allergy, Asthma and Immunology*, **2010**, 105, 430-436.e2	3.2	20
6	Oral sulforaphane increases Phase II antioxidant enzymes in the human upper airway. *Clinical Immunology*, **2009**, 130, 244-51	9	176
5	When is prophylaxis for hereditary angioedema necessary?. *Annals of Allergy, Asthma and Immunology*, **2009**, 102, 366-72	3.2	71
4	Importance of oxidative stress in the pathogenesis and treatment of asthma. *Current Opinion in Allergy and Clinical Immunology*, **2008**, 8, 49-56	3.3	151

3	Dose effects of respiratory neoantigen exposure on primary allergic sensitization. *Clinical Pharmacology and Therapeutics*, **2005**, 77, P3-P3	6.1	
2	Initial high-dose nasal allergen exposure prevents allergic sensitization to a neoantigen. *Journal of Immunology*, **2005**, 174, 7440-5	5.3	26
1	Adverse drug reactions: types and treatment options. *American Family Physician*, **2003**, 68, 1781-90	1.3	132